U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H14ClNS
Molecular Weight 263.7872
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TICLOPIDINE

SMILES

c1ccc(c(c1)CN2CCc3c(ccs3)C2)Cl

InChI

InChIKey=PHWBOXQYWZNQIN-UHFFFAOYSA-N
InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2

HIDE SMILES / InChI

Molecular Formula C14H14ClNS
Molecular Weight 263.7872
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Ticlopidine is a prodrug that is metabolized to an as yet undetermined metabolite that acts as a platelet aggregation inhibitor. Inhibition of platelet aggregation causes a prolongation of bleeding time. In its prodrug form, ticlopidine has no significance in vitro activity at the concentrations attained in vivo. The active metabolite of ticlopidine prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. Ticlopidine is FDA approved for the prevention of strokes and, when combined with aspirin, for patients with a new coronary stent to prevent closure. There are also several off-label uses, including acute treatment of myocardial infarction and unstable angina, peripheral vascular disease, prevention of myocardial infarctions, diabetic retinopathy, and sickle cell disease. The most serious side effects associated with ticlopidine are those that affect the blood cells, although these life-threatening complications are relatively rare.

Originator

Sources: European Journal of Medicinal Chemistry (1974), 9, (5), 487-90.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
TICLID

Approved Use

Ticlopidine hydrochloride tablets are indicated: to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see BOX WARNING and WARNINGS ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see CLINICAL TRIALS ).

Launch Date

688867200000
Preventing
TICLID

Approved Use

Ticlopidine hydrochloride tablets are indicated: to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see BOX WARNING and WARNINGS ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see CLINICAL TRIALS ).

Launch Date

688867200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
365.3 ng/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TICLOPIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1053.9 ng × h/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TICLOPIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.46 h
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TICLOPIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
TICLOPIDINE plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 64.7
Health Status: unhealthy
Age Group: 64.7
Sex: M+F
Sources:
Other AEs: Leukopenia, Neutropenia...
Other AEs:
Leukopenia (4 patients)
Neutropenia (14 patients)
Aspartate aminotransferase increased (13 patients)
ALT increased (36 patients)
Gamma GT increased (54 patients)
ALP increased (2 patients)
Cerebral hemorrhage (1 patient)
Gastric ulcer hemorrhage (1 patient)
Melena (1 patient)
Epistaxis (2 patients)
Rash (1 patient)
Sources:
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, 70
Health Status: unhealthy
Age Group: 70
Sex: F
Sources:
Disc. AE: Agranulocytosis, AST increased...
AEs leading to
discontinuation/dose reduction:
Agranulocytosis (1 patient)
AST increased (1 patient)
ALT increased (1 patient)
Gamma GT increased (1 patient)
ALP increased (1 patient)
Sources:
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Disc. AE: Diarrhea, Nausea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (12.5%)
Nausea (7%)
Dyspepsia (7%)
Rash (5.1%)
GI pain (3.7%)
Neutropenia (2.4%)
Purpura (2.2%)
Vomiting (1.9%)
Flatulence (1.5%)
Pruritus (1.3%)
Dizziness (1.1%)
Anorexia (1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Cerebral hemorrhage 1 patient
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 64.7
Health Status: unhealthy
Age Group: 64.7
Sex: M+F
Sources:
Gastric ulcer hemorrhage 1 patient
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 64.7
Health Status: unhealthy
Age Group: 64.7
Sex: M+F
Sources:
Melena 1 patient
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 64.7
Health Status: unhealthy
Age Group: 64.7
Sex: M+F
Sources:
Rash 1 patient
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 64.7
Health Status: unhealthy
Age Group: 64.7
Sex: M+F
Sources:
Aspartate aminotransferase increased 13 patients
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 64.7
Health Status: unhealthy
Age Group: 64.7
Sex: M+F
Sources:
Neutropenia 14 patients
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 64.7
Health Status: unhealthy
Age Group: 64.7
Sex: M+F
Sources:
ALP increased 2 patients
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 64.7
Health Status: unhealthy
Age Group: 64.7
Sex: M+F
Sources:
Epistaxis 2 patients
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 64.7
Health Status: unhealthy
Age Group: 64.7
Sex: M+F
Sources:
ALT increased 36 patients
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 64.7
Health Status: unhealthy
Age Group: 64.7
Sex: M+F
Sources:
Leukopenia 4 patients
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 64.7
Health Status: unhealthy
Age Group: 64.7
Sex: M+F
Sources:
Gamma GT increased 54 patients
200 mg 1 times / day multiple, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 64.7
Health Status: unhealthy
Age Group: 64.7
Sex: M+F
Sources:
ALP increased 1 patient
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, 70
Health Status: unhealthy
Age Group: 70
Sex: F
Sources:
ALT increased 1 patient
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, 70
Health Status: unhealthy
Age Group: 70
Sex: F
Sources:
AST increased 1 patient
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, 70
Health Status: unhealthy
Age Group: 70
Sex: F
Sources:
Agranulocytosis 1 patient
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, 70
Health Status: unhealthy
Age Group: 70
Sex: F
Sources:
Gamma GT increased 1 patient
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, 70
Health Status: unhealthy
Age Group: 70
Sex: F
Sources:
Anorexia 1%
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Dizziness 1.1%
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Pruritus 1.3%
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Flatulence 1.5%
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Vomiting 1.9%
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Diarrhea 12.5%
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Purpura 2.2%
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Neutropenia 2.4%
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
GI pain 3.7%
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Rash 5.1%
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Dyspepsia 7%
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Nausea 7%
Disc. AE
250 mg 2 times / day multiple, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: multiple
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
OverviewDrug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
Drug-induced thrombotic microangiopathy: incidence, prevention and management.
2001
The use of antiplatelet agents in acute cardiac care.
2001 Apr
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
2001 Apr
Aspirin in patients with coronary artery disease: is it simply irresistible?
2001 Apr
Drug-induced cholestasis.
2001 Apr
[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
2001 Apr
Extracorporeal shockwave lithotripsy in patients treated with antithrombotic agents.
2001 Apr
[Pressure wire guide provisional coronary stent implantation].
2001 Apr
Clinical and angiographical follow-up after implantation of a 6--12 microCi radioactive stent in patients with coronary artery disease.
2001 Apr
Results of CURE trial for acute coronary syndrome.
2001 Apr 11
Long-term effects of intracoronary beta-radiation in balloon- and stent-injured porcine coronary arteries.
2001 Apr 24
Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications.
2001 Apr 24
[Acute heart attacks. Prognosis can be further improved].
2001 Apr 5
Susac's syndrome: beneficial effects of corticosteroid therapy in a Japanese case.
2001 Feb
Antiplatelet therapy in the elderly. Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists.
2001 Feb
Thrombolysis and antithrombotic therapy for coronary artery disease.
2001 Feb
Antithrombotic and thrombolytic therapy for ischemic stroke.
2001 Feb
[Late stent thrombosis after intracoronary brachytherapy. A case report and review of the literature].
2001 Feb
Protective effects of SM-20302, an orally active GPIIb/IIIa antagonist, in an ADP/epinephrine-induced guinea pig model of transient cerebral ischemia.
2001 Feb 1
Fatal aplastic anaemia associated with clopidogrel.
2001 Feb 10
Role of transforming growth factor beta1 in microvascular endothelial cell apoptosis associated with thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome.
2001 Jan
[Early hepatopathy induced by ticlopidine].
2001 Jan
[Clopidogrel? Known or known?].
2001 Jan
[The new limitations of the Italian Regulatory Agency on Drugs].
2001 Jan
[2 platelet inhibitors administered at the same time. Improved prognosis in myocardial infarct?]].
2001 Jan 11
The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease.
2001 Jul
Extensive thrombus prior to elective percutaneous coronary intervention.
2001 Jul
Diffuse alveolar hemorrhage after clopidogrel use.
2001 Jul
[Toxic skin reaction to clopidogrel].
2001 Jun
Low-pressure deployment of stents: short- and long-term outcome.
2001 Jun
Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.
2001 Jun
Ticlopidine-induced interstitial pulmonary disease: a case report.
2001 Jun
Comparative trial of stent-like balloon angioplasty versus coronary stenting for acute myocardial infarction.
2001 Jun
Clinical correlates and drug treatment of residents with stroke in long-term care.
2001 Jun
Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen.
2001 Jun 15
Stenting of partial and total coronary occlusions in Trinidad and Tobago.
2001 Mar
Platelet aggregation inhibition with ticlopidine in the treatment of stroke.
2001 Mar
[Acute coronary syndromes: an update. II. Coronary revascularization and risk stratification].
2001 Mar
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
2001 Mar
Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel.
2001 Mar
Usefulness of intracoronary angioscopy for elucidating the cause of subacute thrombosis after stenting.
2001 Mar
Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs.
2001 Mar
Efficacy of heparin-coated stent in early setting of acute myocardial infarction.
2001 Mar
Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial.
2001 Mar 13
Thrombotic thrombocytopenic purpura--a syndrome caused by multiple pathogenetic mechanisms.
2001 May
Cardiovascular drug-drug interactions.
2001 May
Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.
2001 May
Edge stenosis after intracoronary radiotherapy: angiographic, intravascular, and histological findings.
2001 May 1
Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS).
2001 May 15
P2y(12), a new platelet ADP receptor, target of clopidogrel.
2001 May 4
Patents

Sample Use Guides

250 mg PO q12hr with food
Route of Administration: Oral
In Vitro Use Guide
Following preparation of the platelet concentrate, 1.2 mL of ThromboSol was added to some units (treated units) through a sterile port. We then resuspended the
Substance Class Chemical
Created
by admin
on Sat Jun 26 05:53:15 UTC 2021
Edited
by admin
on Sat Jun 26 05:53:15 UTC 2021
Record UNII
OM90ZUW7M1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TICLOPIDINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
TICLOPIDINE [MI]
Common Name English
TICLOPIDINE [WHO-DD]
Common Name English
TICLOPIDINE [VANDF]
Common Name English
TICLOPIDINE [INN]
Common Name English
TICLOPIDIN-PUREN
Brand Name English
Classification Tree Code System Code
NDF-RT N0000175578
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
NCI_THESAURUS C80483
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
LIVERTOX 963
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
NDF-RT N0000008832
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
WHO-ATC B01AC05
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
NDF-RT N0000008832
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
WHO-VATC QB01AC05
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
Code System Code Type Description
EPA CompTox
55142-85-3
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY
CAS
55142-85-3
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY
WIKIPEDIA
TICLOPIDINE
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY
IUPHAR
7307
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY
RXCUI
10594
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
2657
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY
MESH
D013988
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY
ECHA (EC/EINECS)
259-498-5
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY
PUBCHEM
5472
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY
MERCK INDEX
M10855
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY Merck Index
FDA UNII
OM90ZUW7M1
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY
NCI_THESAURUS
C61972
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY
EVMPD
SUB11028MIG
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL833
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY
DRUG BANK
DB00208
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY
INN
3908
Created by admin on Sat Jun 26 05:53:16 UTC 2021 , Edited by admin on Sat Jun 26 05:53:16 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
IN VITRO
METABOLITE -> PARENT
IN VITRO
Related Record Type Details
ACTIVE MOIETY